Therapy Areas: AIDS & HIV
Janssen Touts Positive Long-Term Efficacy and Safety of Symtuza (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1
1 November 2018 - - US-based healthcare company Johnson and Johnson's (NYSE: JNJ) The Janssen Pharmaceutical Companies business has unveiled 96-week results from the pivotal Phase 3 AMBER study of Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (D/C/F/TAF)) at HIV Glasgow in Scotland, the company said.

D/C/F/TAF is a once-daily darunavir-based single-tablet regimen, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg.

Genotypic testing should guide the use of D/C/F/TAF.

Results from the AMBER study demonstrated that a high proportion of antiretroviral treatment -naïve adults with HIV-1 (85%, 308/362) maintained virologic suppression (viral load
Login
Username:

Password: